MicroRNAs (miRNAs) in Cardiovascular Complications of Rheumatoid Arthritis (RA): What Is New?
International Journal of Molecular Sciences
; 23(9):5254, 2022.
Article
in English
| ProQuest Central | ID: covidwho-1843155
ABSTRACT
Rheumatoid Arthritis (RA) is among the most prevalent and impactful rheumatologic chronic autoimmune diseases (AIDs) worldwide. Within a framework that recognizes both immunological activation and inflammatory pathways, the exact cause of RA remains unclear. It seems however, that RA is initiated by a combination between genetic susceptibility, and environmental triggers, which result in an auto-perpetuating process. The subsequently, systemic inflammation associated with RA is linked with a variety of extra-articular comorbidities, including cardiovascular disease (CVD), resulting in increased mortality and morbidity. Hitherto, vast evidence demonstrated the key role of non-coding RNAs such as microRNAs (miRNAs) in RA, and in RA-CVD related complications. In this descriptive review, we aim to highlight the specific role of miRNAs in autoimmune processes, explicitly on their regulatory roles in the pathogenesis of RA, and its CV consequences, their main role as novel biomarkers, and their possible role as therapeutic targets.
Chemistry--Organic Chemistry; microRNAs; miRNAs; rheumatoid arthritis; RA; cardiovascular complications; CVD; atherosclerosis; pericarditis; myocardial infarction; Morbidity; miRNA; Therapeutic targets; Cardiovascular diseases; Arthritis; Biomarkers; Pathogenesis; Autoimmune diseases; Coronaviruses; Immunology; Heart diseases; COVID-19; Inflammation
Search on Google
Collection:
Databases of international organizations
Database:
ProQuest Central
Language:
English
Journal:
International Journal of Molecular Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS